BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 30963606)

  • 21. 177Lu-AMBA: Synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer.
    Lantry LE; Cappelletti E; Maddalena ME; Fox JS; Feng W; Chen J; Thomas R; Eaton SM; Bogdan NJ; Arunachalam T; Reubi JC; Raju N; Metcalfe EC; Lattuada L; Linder KE; Swenson RE; Tweedle MF; Nunn AD
    J Nucl Med; 2006 Jul; 47(7):1144-52. PubMed ID: 16818949
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Positron Emission Tomography Imaging of Prostate Cancer with Ga-68-Labeled Gastrin-Releasing Peptide Receptor Agonist BBN
    Cheng S; Lang L; Wang Z; Jacobson O; Yung B; Zhu G; Gu D; Ma Y; Zhu X; Niu G; Chen X
    Bioconjug Chem; 2018 Feb; 29(2):410-419. PubMed ID: 29254329
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular imaging, pharmacokinetics, and dosimetry of In-AMBA in human prostate tumor-bearing mice.
    Ho CL; Liu IH; Wu YH; Chen LC; Chen CL; Lee WC; Chuang CH; Lee TW; Lin WJ; Shen LH; Chang CH
    J Biomed Biotechnol; 2011; 2011():101497. PubMed ID: 21660132
    [TBL] [Abstract][Full Text] [Related]  

  • 24. microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts.
    Chen X; Park R; Hou Y; Tohme M; Shahinian AH; Bading JR; Conti PS
    J Nucl Med; 2004 Aug; 45(8):1390-7. PubMed ID: 15299066
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical pharmacokinetic, biodistribution, imaging and therapeutic efficacy of (177)Lu-Labeled glycated bombesin analogue for gastrin-releasing peptide receptor-positive prostate tumor targeting.
    Lim JC; Cho EH; Kim JJ; Choi SM; Lee SY; Nam SS; Park UJ; Park SH
    Nucl Med Biol; 2015 Mar; 42(3):234-41. PubMed ID: 25498002
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gastrin releasing peptide receptor-directed radioligands based on a bombesin antagonist: synthesis, (111)in-labeling, and preclinical profile.
    Marsouvanidis PJ; Nock BA; Hajjaj B; Fehrentz JA; Brunel L; M'Kadmi C; van der Graaf L; Krenning EP; Maina T; Martinez J; de Jong M
    J Med Chem; 2013 Mar; 56(6):2374-84. PubMed ID: 23427837
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
    Zhang H; Desai P; Koike Y; Houghton J; Carlin S; Tandon N; Touijer K; Weber WA
    J Nucl Med; 2017 Jan; 58(1):29-35. PubMed ID: 27516447
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with rapamycin.
    Dumont RA; Tamma M; Braun F; Borkowski S; Reubi JC; Maecke H; Weber WA; Mansi R
    J Nucl Med; 2013 May; 54(5):762-9. PubMed ID: 23492884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. N-terminal modifications improve the receptor affinity and pharmacokinetics of radiolabeled peptidic gastrin-releasing peptide receptor antagonists: examples of 68Ga- and 64Cu-labeled peptides for PET imaging.
    Gourni E; Mansi R; Jamous M; Waser B; Smerling C; Burian A; Buchegger F; Reubi JC; Maecke HR
    J Nucl Med; 2014 Oct; 55(10):1719-25. PubMed ID: 25146125
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist
    Mitran B; Rinne SS; Konijnenberg MW; Maina T; Nock BA; Altai M; Vorobyeva A; Larhed M; Tolmachev V; de Jong M; Rosenström U; Orlova A
    Int J Cancer; 2019 Dec; 145(12):3347-3358. PubMed ID: 31077356
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Matched-pair,
    Bandara N; Stott Reynolds TJ; Schehr R; Bandari RP; Diebolder PJ; Krieger S; Xu J; Miao Y; Rogers BE; Smith CJ
    Nucl Med Biol; 2018; 62-63():71-77. PubMed ID: 29929115
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biological evaluation of (177)Lu-labeled DOTA-Ala(SO3H)-Aminooctanoyl-Gln-Trp-Ala-Val-N methyl Gly-His-Statine-Leu-NH2 for gastrin-releasing peptide receptor-positive prostate tumor targeting.
    Lim JC; Cho EH; Kim JJ; Choi SM; Lee Sy; Nam SS; Park UJ; Park SH
    Nucl Med Biol; 2015 Feb; 42(2):131-6. PubMed ID: 25457455
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical comparison of Al18F- and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer.
    Chatalic KL; Franssen GM; van Weerden WM; McBride WJ; Laverman P; de Blois E; Hajjaj B; Brunel L; Goldenberg DM; Fehrentz JA; Martinez J; Boerman OC; de Jong M
    J Nucl Med; 2014 Dec; 55(12):2050-6. PubMed ID: 25413139
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis, and biological evaluation of an antagonist-bombesin analogue as targeting vector.
    Abd-Elgaliel WR; Gallazzi F; Garrison JC; Rold TL; Sieckman GL; Figueroa SD; Hoffman TJ; Lever SZ
    Bioconjug Chem; 2008 Oct; 19(10):2040-8. PubMed ID: 18808168
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preclinical Evaluation of the Copper-64 Labeled GRPR-Antagonist RM26 in Comparison with the Cobalt-55 Labeled Counterpart for PET-Imaging of Prostate Cancer.
    Baun C; Mitran B; Rinne SS; Dam JH; Olsen BB; Tolmachev V; Orlova A; Thisgaard H
    Molecules; 2020 Dec; 25(24):. PubMed ID: 33352838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GRPR-selective PET imaging of prostate cancer using [(18)F]-lanthionine-bombesin analogs.
    Carlucci G; Kuipers A; Ananias HJ; de Paula Faria D; Dierckx RA; Helfrich W; Rink R; Moll GN; de Jong IJ; Elsinga PH
    Peptides; 2015 May; 67():45-54. PubMed ID: 25797109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Receptor-binding, biodistribution, dosimetry, and micro-SPECT/CT imaging of 111In-[DTPA(1), Lys(3), Tyr(4)]-bombesin analog in human prostate tumor-bearing mice.
    Ho CL; Chen LC; Lee WC; Chiu SP; Hsu WC; Wu YH; Yeh CH; Stabin MG; Jan ML; Lin WJ; Lee TW; Chang CH
    Cancer Biother Radiopharm; 2009 Aug; 24(4):435-43. PubMed ID: 19694578
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical evaluation of a novel ¹¹¹In-labeled bombesin homodimer for improved imaging of GRPR-positive prostate cancer.
    Carlucci G; Ananias HJ; Yu Z; Hoving HD; Helfrich W; Dierckx RA; Liu S; de Jong IJ; Elsinga PH
    Mol Pharm; 2013 May; 10(5):1716-24. PubMed ID: 23590837
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer.
    Zhang X; Cai W; Cao F; Schreibmann E; Wu Y; Wu JC; Xing L; Chen X
    J Nucl Med; 2006 Mar; 47(3):492-501. PubMed ID: 16513619
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stability Evaluation and Stabilization of a Gastrin-Releasing Peptide Receptor (GRPR) Targeting Imaging Pharmaceutical.
    Ghosh A; Woolum K; Kothandaraman S; Tweedle MF; Kumar K
    Molecules; 2019 Aug; 24(16):. PubMed ID: 31398865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.